NewsResearch
Decentralized Cancer Trials: Bringing Parts of Research Closer to Home
Some trials use local labs, telehealth, home monitoring, or mailed medicines. These methods can reduce travel but do not fit every study.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What FDA means by decentralized elements
The word decentralized sounds vague. FDA's definition is not.
FDA describes decentralized elements as trial activities that happen remotely, at places convenient for the participant. Its own examples are telehealth visits with trial staff, in-home visits by remote trial personnel, and visits with local health care providers.
A decentralized clinical trial, in FDA's wording, is a trial that includes such elements, where some activities occur at locations other than traditional trial sites. FDA has published guidance for sponsors and investigators on how to put them in place.
Notice the word elements. It is not all or nothing. Most trials that use these methods still have a research center at the center of them.
This page explains federal sources. It is not medical advice and does not suggest a test or treatment.
What actually moves
In practice, the parts that can shift closer to home include:
- routine check-in visits, done by video
- blood draws at a local laboratory
- some imaging at a nearby facility
- symptom and side-effect tracking through an app or a wearable device
- study medicine shipped to the participant
- parts of the consent process, handled remotely
What does not move
Some procedures still need an experienced research site with the right staff and equipment. A first dose of a new drug, a biopsy, or a treatment that carries a risk of severe reactions is not something to attempt at a kitchen table.
Eligibility does not become looser either. NCI notes that every trial has requirements a person must meet, covering health, medical history, family history, risk factors, age, treatment history, and the tumor's genetic changes. Those exist to protect participants and to keep the results interpretable.
Convenience is not the same as access
Remote visits reduce travel. They do not remove every burden, and some burdens simply move.
Someone has to be at home for an in-home visit. Someone has to manage the device. Reliable internet, a suitable phone or computer, language support, and caregiver time all become part of the study, and they are not evenly distributed.
NCI's own guidance on finding a trial keeps a practical question front and center: is the location of the trial manageable for you? Some trials run at more than one location. And when you have found one, the protocol summary should include a phone number for someone you can contact. NCI suggests you can ask your doctor or another member of your care team to make that call for you.
Money is a separate question from convenience. Our page on who pays for the experimental treatment in a trial covers what is usually covered and what is not.
How to tell whether it worked
The measure is not enrollment alone. A trial can enroll faster and still fail the people in it.
Better evidence compares participation, safety reporting, missing data, and how many people stayed in the study, before and after a remote feature was added. It also asks participants directly which burdens fell away and which shifted to the home or the local clinic.
The real test is whether people from more communities could take part safely and stay to the end.
The rules that do not change
- Decentralized does not mean every visit can happen at home.
- More convenience does not reduce the risks of an experimental treatment.
- Digital tools can create new barriers for people without reliable devices or internet.
- Data quality, participant safety, privacy, and informed consent still have to be protected. FDA's guidance is largely about how.
Before joining anything, what clinical trials are and the risks and questions involved in joining one are the places to start.
Questions before joining a remote trial
- Which visits and tests can happen locally, and which cannot?
- Who responds if I have symptoms at 2 a.m., or if the device stops working?
- Who is my local contact, and can they reach the research center?
- Are devices, internet, travel, and caregiver costs covered?
- What happens if I cannot keep up with the remote monitoring?
How this article was prepared
An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.
The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Decentralized cancer trials. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.